The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...

SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending the 24th Annual Needham Virtual Healthcare Conference taking place ...

FibroGen (FGEN) announced the peer-reviewed publication titled “A Phase 1, First-in-Human Study of FOR46, an Immune-Modulating Antibody-Drug ...

Q4 2024 Earnings Call Transcript March 17, 2025 FibroGen, Inc. reports earnings inline with expectations. Reported EPS is $-0.08 EPS, expectations were $-0.08. Operator: Hello everyone, and welcome to ...

Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), expected ...

FibroGen, Inc. (NASDAQ: FGEN) today announced the peer-reviewed publication titled “A Phase 1, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in ...

Detailed price information for Fibrogen Inc CS (FGEN-Q) from The Globe and Mail including charting and trades.

(NASDAQ: FGEN) today announced the peer-reviewed publication titled “A Phase 1, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients with ...